±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 1082  |  »Ø¸´: 1
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

csu03712

ľ³æ (ÖøÃûдÊÖ)

[ÇóÖú] ÇóÖú·­ÒëÒ»¶ÎÓ¢ÎÄÎÄÏ×£¨¸ß·Ö×ӾۺϷ½Ïò£©

Ò²¿ÉÒÔ·­ÒëÆäÖÐÒ»¶Î£¬Ð»Ð»£¡
      Bacterial drug resistance has become a serious problem in hospitals and community environments, as currently used treatments with broad-spectrum antibiotics are becoming progressively less effective.1 One of the most dangerous
human pathogens in this regard is methicillin-resistant Staphylococcus aureus (MRSA), an opportunistic microbe commonly found in skin abrasions and open wounds.

       Without treatment, these drug-resistant infections can lead  rapidly to the onset of bacteremia, sepsis, and toxic shock  syndrome.2-4 Drug-resistant infections claim thousands of  lives annually in the United States, and antibiotic therapy has  been reduced to only a few approved therapies. This problem
will most certainly continue to escalate as antibiotic resistance becomes even more widespread and serious. In addition to issues relating to acquired antibiotic resistance, many antibiotics are generally less effective in treating infections in fatty tissue, biofilms, or along the surfaces of bone and artificial devices where drug-resistant bacterial infections are so often found.9 Some lipophilic antimicrobials
are also limited to topical application because of their low water solubility for systemic administration.

     Our laboratory has become interested in exploring the use of nanoparticle-based antibiotics as potential treatments for life-threatening bacterial infections. One obvious use of the nanoparticles would be for enhancing performance of
antibacterial drugs that otherwise suffers from poor water solubility, stability, toxicity, or pharmacokinetics and distribution. Many lipid, phospholipid, and triglyceride-based emulsions containing droplets at the submicron level have
shown benefits when used for drug delivery, including delivering the dissolved drug solely to its intended destination in the body, providing the drug with controlled release, increasing the uptake and efficiency of the drug, and also reducing the inherent toxicity of the drug monomer, as in the case of amphotericin B.11-18 More recently, nanoparticles made from metals, fullerenes, synthetic and natural polymers, and various lipids have been investigated for certain drug delivery applications,19-25 a process wrought with questions and concerns relating to their ultimate benefits, applications, and potential drawbacks. One of the major concerns with the use of nanomaterials is the heightened risk of toxicity due to their extremely small size, their physical properties, their unknown chemical and biochemical interactions, as well as their ease of penetration through cellular and blood-brain barriers. Toxicological analysis of metal-based nanoparticles
in solution has been underway for some time,20,22,24; however, evaluation of new nanoparticle materials for cytotoxic or systemic toxicity has not kept up with the rapid evolution of the nanotechnology field. Polyacrylates have been used since the 1960s as biomedical coatings on devices and surgical glues, and are considered nontoxic26-35; moreover, emulsified polyacrylates, likewise, have been
studied as colloidal drug carriers.11-18,28,36-41 However, data on toxicity and biocompatibility of polyacrylate nanoparticles  (having diameters b100 nm) is severely lacking.

» ²ÂÄãϲ»¶

»°ËµÎÒµÄÍ·ÏñºÜ»ÎÑÛ¡¤¡¤¡¤¡¤¡¤¡¤
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ʯ¾°ºê

½û³æ (ÕýʽдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

csu03712(½ð±Ò+5, ·­ÒëEPI+1): 2011-05-12 09:58:18
ÔÚÒ½ÔººÍÉçÇø»·¾³ÖÐϸ¾úµÄ¿¹Ò©ÐÔÒѾ­³ÉΪһ¸öÑÏÖØµÄÎÊÌ⣬Èçµ±ÏÂËùÓõĹâÆ×¿¹Ò©ÐÔ·½·¨Öð½¥Ê§È¥Ð§¹û£¬ÆäÖÐÔÚÕâ·½ÃæÌåÏÖÍ»³öµÄÊÇÒ»ÖÖ×îÀ÷º¦µÄÈËÀಡԭÌåÄͼ×ÑõÎ÷ÁÖ½ðÆÏ¾ú£¬ÔÚÆ¤·ô²ÁÉË´¦ºÍ¿ª·ÅÐÔÉ˿ڴ¦¾­³£·¢ÏÖÒ»ÖÖ»ú»áÐÔµÄ΢ÉúÎï¡£
½¡¿µ¿ìÀֵĻîמÍÊÇ×î´óµÄÐÒ¸££¡
2Â¥2011-05-11 12:05:48
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ csu03712 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁÏר˶322 +11 ¹þ¹þ¹þºðºðºð¹þ 2026-04-05 11/550 2026-04-06 14:07 by lqwchd
[¿¼ÑÐ] 0857´óÀà»·¾³¹¤³ÌBÇøÇóµ÷¼Á +3 ¹¨ÓíÃú 2026-04-05 3/150 2026-04-06 10:22 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 285Çóµ÷¼Á +12 ŶßϺôo 2026-04-04 12/600 2026-04-06 09:48 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 08ר˶275µ÷¼Á +5 AaAa7420 2026-04-05 5/250 2026-04-05 18:01 by jkddd
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖØÇì´óѧ085404£¬×Ü·Ö314·Ö£¬Çóµ÷¼Á +4 zf83hn 2026-04-03 4/200 2026-04-03 21:25 by à£à£à£0119
[¿¼ÑÐ] Ò»Ö¾Ô¸Äϲý´óѧ324Çóµ÷¼Á +13 hanamiko 2026-04-01 13/650 2026-04-03 18:30 by lsÁõ˧
[¿¼ÑÐ] 338Çóµ÷¼Á +7 êɹ¦? 2026-04-03 7/350 2026-04-03 16:46 by wxiongid
[¿¼ÑÐ] 274Çóµ÷¼Á +9 ˳Àí³ÉÕÅ 2026-04-03 10/500 2026-04-03 15:10 by °¡¿¡£¡
[¿¼ÑÐ] »úеר˶297 +3 Afksy 2026-04-03 3/150 2026-04-03 14:24 by 1753564080
[¿¼ÑÐ] 311Çóµ÷¼ÁÒ»Ö¾Ô¸ºÏ·Ê¹¤Òµ´óѧ +15 Çï¶þÊ®¶þ 2026-03-30 15/750 2026-04-03 10:19 by linyelide
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +6 ÏàÐűػá¹ââÍòÕ 2026-03-31 7/350 2026-04-02 23:16 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸´ó¹¤Ñ§Ë¶£¬Çóµ÷¼Á +4 yub0811 2026-04-02 4/200 2026-04-02 21:36 by °ÙÁéͯ888
[¿¼ÑÐ] 296Çóµ÷¼Á +4 sdhu 2026-04-02 4/200 2026-04-02 21:29 by baoball
[¿¼ÑÐ] Çóµ÷¼Á +7 Aniyaio 2026-04-02 7/350 2026-04-02 16:42 by zzsw+
[¿¼ÑÐ] µ÷¼Á +3 ºÃºÃ¶ÁÊé¡£ 2026-04-01 6/300 2026-04-02 15:49 by liumengping
[¿¼ÑÐ] 266Çóµ÷¼Á +4 ѧԱ97LZgn 2026-04-02 4/200 2026-04-02 13:03 by yulian1987
[¿¼ÑÐ] 0710ÉúÎïѧ£¬325Çóµ÷¼Á +3 mkkkkkl 2026-04-01 3/150 2026-04-02 09:48 by Jaylen.
[¿¼ÑÐ] 377Çóµ÷¼Á +3 RASKIN 2026-04-02 3/150 2026-04-02 09:45 by zzchen2000
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +10 Eujd1 2026-03-31 11/550 2026-04-01 11:23 by ivanqyq
[¿¼ÑÐ] 085601Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ³õÊÔ346 +4 085601³õÊÔ346 2026-03-30 4/200 2026-03-31 07:47 by jp9609
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û